LRRK2 and myeloid sarcoma: In addition, neuropathological findings support that homozygous LRRK2 mutations are not associated with worse brain pathology than heterozygote LRRK2 mutations, though we cannot exclude the possibility that, in this case, LRRK2 homozygosity may have contributed to the development of MS.